Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Wun

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
British Journal of Haematology|June 20, 2024
The clinical spectrum of HbSC sickle cell disease-not a benign conditionM Nelson, L Noisette, N Pugh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollmentP N Lara, R Higdon, N Lim, et al.
JAMA|November 22, 2001
Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trialE P Orringer, J F Casella, K I Ataga, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
British Journal of Haematology|June 20, 2024
The clinical spectrum of HbSC sickle cell disease-not a benign conditionM Nelson, L Noisette, N Pugh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollmentP N Lara, R Higdon, N Lim, et al.
JAMA|November 22, 2001
Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trialE P Orringer, J F Casella, K I Ataga, et al.
Pageof 6